Literature DB >> 21531574

Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis.

Sascha David1, Joon-Keun Park, Matijs van Meurs, Jan G Zijlstra, Christian Koenecke, Claudia Schrimpf, Nelli Shushakova, Faikah Gueler, Hermann Haller, Philipp Kümpers.   

Abstract

INTRODUCTION: Endothelial activation leading to vascular barrier breakdown plays an essential role in the pathophysiology of multiple-organ dysfunction syndrome (MODS) in sepsis. Increasing evidence suggests that the function of the vessel-protective factor Angiopoietin-1 (Ang-1), a ligand of the endothelial-specific Tie2 receptor, is inhibited by its antagonist Angiopoietin-2 (Ang-2) during sepsis. In order to reverse the effects of the sepsis-induced suppression of Ang-1 and elevation of Ang-2 we aimed to investigate whether an intravenous injection of recombinant human (rh) Ang-1 protects against MODS in murine sepsis.
METHODS: Polymicrobiological abdominal sepsis was induced by cecal ligation and puncture (CLP). Mice were treated with either 1 μg of intravenous rhAng-1 or control buffer immediately after CLP induction and every 8h thereafter. Sham-operated animals served as time-matched controls.
RESULTS: Compared to buffer-treated controls, rhAng-1 treated septic mice showed significant improvements in several hematologic and biochemical indicators of MODS. Moreover, rhAng-1 stabilized endothelial barrier function, as evidenced by inhibition of protein leakage from lung capillaries into the alveolar compartment. Histological analysis revealed that rhAng-1 treatment attenuated leukocyte infiltration in lungs and kidneys of septic mice, probably due to reduced endothelial adhesion molecule expression in rhAng-1 treated mice. Finally, the protective effects of rhAng-1 treatment were reflected by an improved survival time in a lethal CLP model.
CONCLUSIONS: In a clinically relevant murine sepsis model, intravenous rhAng-1 treatment alone is sufficient to significantly improve a variety of sepsis-associated organ dysfunctions and survival time, most likely by preserving endothelial barrier function. Further studies are needed to pave the road for clinical application of this therapy concept.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21531574     DOI: 10.1016/j.cyto.2011.04.005

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  47 in total

1.  Angiopoietin-2 is a potential mediator of endothelial barrier dysfunction following cardiopulmonary bypass.

Authors:  Christian Clajus; Alexander Lukasz; Sascha David; Barbara Hertel; Ralf Lichtinghagen; Samir M Parikh; André Simon; Issam Ismail; Hermann Haller; Philipp Kümpers
Journal:  Cytokine       Date:  2012-07-06       Impact factor: 3.861

2.  Higher Plasma Endothelial Markers in Adults with Cystic Fibrosis Compared with Healthy Age-matched Control Subjects.

Authors:  Pavan K Bhatraju; Katie B Hisert; Moira L Aitken; Christopher H Goss; W Conrad Liles; William A Altemeier
Journal:  Ann Am Thorac Soc       Date:  2019-06

3.  Dysregulation of angiopoietin 1 and 2 in Escherichia coli O157:H7 infection and the hemolytic-uremic syndrome.

Authors:  Andrea V Page; Phillip I Tarr; Sandra L Watkins; Nimerta Rajwans; Tania N Petruzziello-Pellegrini; Philip A Marsden; Kevin C Kain; W Conrad Liles
Journal:  J Infect Dis       Date:  2013-06-24       Impact factor: 5.226

4.  von Willebrand factor and angiopoietin-2: toward an acute lung injury endothelial endophenotype?

Authors:  Nuala J Meyer; Jason D Christie
Journal:  Crit Care Med       Date:  2012-06       Impact factor: 7.598

Review 5.  Therapeutic targeting of the angiopoietin-TIE pathway.

Authors:  Pipsa Saharinen; Lauri Eklund; Kari Alitalo
Journal:  Nat Rev Drug Discov       Date:  2017-05-19       Impact factor: 84.694

Review 6.  Beyond single-nucleotide polymorphisms: genetics, genomics, and other 'omic approaches to acute respiratory distress syndrome.

Authors:  Nuala J Meyer
Journal:  Clin Chest Med       Date:  2014-09-23       Impact factor: 2.878

7.  Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*.

Authors:  Sascha David; Aditi Mukherjee; Chandra C Ghosh; Midori Yano; Eliyahu V Khankin; Julia B Wenger; S Ananth Karumanchi; Nathan I Shapiro; Samir M Parikh
Journal:  Crit Care Med       Date:  2012-11       Impact factor: 7.598

Review 8.  Angiopoietins and Tie2 in vascular inflammation.

Authors:  Samir M Parikh
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

9.  Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients.

Authors:  Ashish Agrawal; Michael A Matthay; Kirsten N Kangelaris; John Stein; Jeffrey C Chu; Brandon M Imp; Alfredo Cortez; Jason Abbott; Kathleen D Liu; Carolyn S Calfee
Journal:  Am J Respir Crit Care Med       Date:  2013-04-01       Impact factor: 21.405

10.  Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis.

Authors:  Tilman Ziegler; Jan Horstkotte; Claudia Schwab; Vanessa Pfetsch; Karolina Weinmann; Steffen Dietzel; Ina Rohwedder; Rabea Hinkel; Lisa Gross; Seungmin Lee; Junhao Hu; Oliver Soehnlein; Wolfgang M Franz; Markus Sperandio; Ulrich Pohl; Markus Thomas; Christian Weber; Hellmut G Augustin; Reinhard Fässler; Urban Deutsch; Christian Kupatt
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.